Biomedical subjects
Publications and source records attributed to J R Rodríguez.
High dietary fat has been consistently linked to breast cancer in epidemiological and experimental studies. This communication reviews the possible mechanisms involved in this relationship. Also we review the effects of different fats on breast cancer growth in recent experimental studies.
We evaluated the hormonal profile and the platelet function in a group of 20 patients with menstrual migraine and a control group of 10 healthy women. Plasma levels of estradiol, progesterone, FSH and LH, as well as betathromboglobulin, platelet factor 4 and platelet serotonin were measured in different phases of the menstrual cycle. The hormonal profile did not show significant differences between both groups. The patients with menstrual migraine had higher BTG, FP4 and serotonin levels in the premenstrual phase than the control group. The results of this study show that in premenstrual migraine a platelet hyperagregation develops during the premenstrual phase. This abnormality is not directly correlated with the hormonal fluctuations observed during the menstrual cycle.
The possibility of abnormal platelet function in patients with tension headache was evaluated with serial plasmatic measurements of serotonin, beta-thromboglobulin and platelet factor 4. In 40 patients with tension headache we found increased serotonin, thromboglobulin and platelet factor 4 levels during the painful phases as compared with the asymptomatic phases. These data might indicate that an increased platelet aggregation plays some role in the pathogenesis of tension headache.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A total of 80 patients were randomized to receive either aztreonam or tobramycin for the treatment of lower respiratory tract infections caused by gram-negative bacilli; all these patients received clindamycin concomitantly. A total of 53 patients were randomized to receive aztreonam-clindamycin; of these, 46 were clinically evaluable and 39 were bacteriologically evaluable. Of the 46 clinically evaluable patients, 41 were considered cured, 3 failed to be cured, and 2 died during the study period of unrelated causes. Of the 39 bacteriologically evaluable patients, 36 were considered cured, and 3 failed to be cured. There were 26 clinically evaluable patients in the group randomized to receive tobramycin-clindamycin. Of them, 22 patients were considered cured, 3 failed to be cured, and 1 died of unrelated causes during the study period. There were 18 bacteriologically evaluable patients in the tobramycin-clindamycin group; 17 were cured, and 1 failed to be cured. The most common pathogens isolated from the patients were Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. All of the isolated organisms were susceptible to both tested antibiotics, except for a strain of Pseudomonas cepacia resistant to both tested antimicrobial agents and a strain of Enterobacter aerogenes and one of P. aeruginosa that were resistant to aztreonam. Very few adverse reactions related to the antibiotics were seen. These effects, when present, were transient and comparable in both studied groups, except for renal-function tests, which were altered in 7.7% of the patients randomized to receive tobramycin-clindamycin and in none of the patients randomized to receive aztreonam-clindamycin. Aztreonam-clindamycin is safe and effective for the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli when the organisms are susceptible.
MICs of 20 2-acetylpyridine thiosemicarbazones and penicillin were determined for 25 clinical isolates of beta-lactamase-positive and beta-lactamase-negative Neisseria gonorrhoeae strains. The compounds most active against the beta-lactamase-producing strains were the N4,N4-disubstituted derivatives and the thiosemicarbazone derivatives of the 2-acetylpyridines, followed by the other compounds related to the 2-acetylpyridine thiosemicarbazones.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.